Dapagliflozin Trial Stirs Controversy

Restricted access

A new trial with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin (brand name Farxiga) is recruiting COVID-19 patients with type 2 diabetes and other conditions to assess whether the drug can reduce COVID-19 progression.

However, the 900-patient, placebo-controlled DARE-19 trial (Dapagliflozin in Respiratory Failure in Patients with COVID-19) with the drug is proving controversial.

The AstraZeneca (Cambridge, UK) trial of dapagliflozin calls for COVID-19 patients with a history that includes at least one of these conditions: type 2 diabetes, hypertension, atherosclerotic cardiovascular disease, heart failure and/or chronic kidney disease stage 3 to 4 (eGFR ≥25 mL/min/1.73 m2).